keyword
MENU ▼
Read by QxMD icon Read
search

isoniazid preventive therapy

keyword
https://www.readbyqxmd.com/read/29297443/screening-for-active-tuberculosis-before-isoniazid-preventive-therapy-among-hiv-infected-west-african-adults
#1
R Moh, A Badjé, J-B N'takpé, G M Kouamé, D Gabillard, T Ouassa, E Ouattara, J Le Carrou, F Bohoussou, E Messou, S Eholié, X Anglaret, C Danel
SETTING: TEMPRANO was a multicentre, open-label trial in which human immunodeficiency virus (HIV) infected adults with high CD4 counts were randomised into early or deferred antiretroviral therapy (ART) arms with or without 6-month isoniazid preventive therapy (IPT) in a setting where the World Health Organization (WHO) recommends IPT in HIV-infected patients. Despite the WHO recommendation, IPT coverage remains low due to fear of the presence of undiagnosed active TB before prescribing IPT, and the related risk of drug resistance...
December 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/29241821/isoniazid-and-rifampicin-concentrations-in-children-with-tuberculosis-on-either-daily-or-intermittent-regimen-implications-for-the-revised-rntcp-2012-doses-in-india
#2
Jaya Ranjalkar, Sumith K Mathew, Valsan Philip Verghese, Anuradha Bose, Winsley Rose, Dulari Gupta, Denise H Fleming, Binu Susan Mathew
BACKGROUND: Sub-optimal plasma drug concentrations of Anti-Tubercular Therapy (ATT) could lead to delayed response and emergence of acquired drug-resistance. OBJECTIVES: To determine and compare the plasma concentrations of isoniazid and rifampicin in children treated for tuberculosis (TB) on daily or intermittent ATT regimen. To study the effect of the exposure of isoniazid and rifampicin on clinical outcome at the end of therapy. METHODS: Forty-one children aged 2 to 16 years, initiated on either daily or three-times a week (intermittent) ATT regimen were recruited into the study...
December 11, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29239900/isoniazid-preventive-therapy-for-people-with-hiv-who-are-heavy-alcohol-drinkers-in-high-tb-hiv-burden-countries-a-risk-benefit-analysis
#3
J Morgan Freiman, Karen R Jacobson, Winnie R Muyindike, C Robert Horsburgh, Jerrold J Ellner, Judith A Hahn, Benjamin P Linas
BACKGROUND: Isoniazid preventive therapy (IPT) reduces mortality among people living with HIV (PLHIV), and is recommended for those without active tuberculosis (TB) symptoms. Heavy alcohol use, however, is contraindicated for liver toxicity concerns. We evaluated the risks and benefits of IPT at antiretroviral therapy (ART) initiation to ART alone for PLHIV who are heavy drinkers in three high TB/HIV burden countries. METHODS: We developed a Markov simulation model to compare ART alone to ART with either 6 or 36 months of IPT for heavy drinking PLHIV enrolling in care in Brazil, India, and Uganda...
December 6, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29201654/increasing-isoniazid-preventive-therapy-uptake-in-an-hiv-program-in-rural-papua-new-guinea
#4
A Carmone, C A Rodriguez, T D Frank, M Kiromat, P W Bongi, R G Kuno, T Palou, M F Franke
Setting: Tuberculosis (TB) is the leading cause of death among people living with the human immunodeficiency virus (PLHIV) in Papua New Guinea. Despite a policy for isoniazid preventive therapy (IPT) among PLHIV, implementation has been slow. Objective: We prospectively evaluated a standardized guided screening process, including TB diagnostic support, to increase IPT initiation in adult PLHIV on antiretro-viral treatment. Design: The guided process included a paper-based IPT screening tool that prompted review of patient history and TB symptoms and sputum analysis by smear microscopy and Xpert® MTB/RIF...
September 21, 2017: Public Health Action
https://www.readbyqxmd.com/read/29187783/the-effect-of-micronutrient-supplementation-on-active-tb-incidence-early-in-hiv-infection-in-botswana
#5
Adriana Campa, Marianna K Baum, Hermann Bussmann, Sabrina Sales Martinez, Mansour Farahani, Erik van Widenfelt, Sikhulile Moyo, Joseph Makhema, Max Essex, Richard Marlink
Background: Coinfection with active tuberculosis (TB) is one of the leading causes of death in people living with HIV (PLWH) in Africa. This investigation explores the role of micronutrient supplementation in preventing active TB in PLWH. Methods: A randomized trial of nutritional supplementation was conducted among antiretroviral- naïve (without previous antiretroviral treatment [ART]) HIV-infected people in Botswana between 2004 and 2009. The study had a factorial design with four arms: the selenium (Se) alone arm, the multivitamins (MVT) alone arm that contained vitamin B complex and vitamins C and E, the combined Se+MVT group and the placebo group...
2017: Nutrition and Dietary Supplements
https://www.readbyqxmd.com/read/29157275/the-prevent-study-to-evaluate-the-effectiveness-and-acceptability-of-a-community-based-intervention-to-prevent-childhood-tuberculosis-in-lesotho-study-protocol-for-a-cluster-randomized-controlled-trial
#6
Yael Hirsch-Moverman, Andrea A Howard, Koen Frederix, Limakatso Lebelo, Anneke Hesseling, Sharon Nachman, Joanne E Mantell, Tsepang Lekhela, Llang Bridget Maama, Wafaa M El-Sadr
BACKGROUND: Effective, evidence-based interventions to prevent childhood tuberculosis (TB) in high TB/HIV-burden, resource-limited settings are urgently needed. There is limited implementation of evidence-based contact management strategies, including isoniazid preventive therapy (IPT), for child contacts of TB cases in Lesotho. METHODS/DESIGN: This mixed-methods implementation science study utilizes a two-arm cluster-randomized trial design with randomization at the health facility level...
November 21, 2017: Trials
https://www.readbyqxmd.com/read/29114781/self-administered-versus-directly-observed-once-weekly-isoniazid-and-rifapentine-treatment-of-latent-tuberculosis-infection-a-randomized-trial
#7
Robert Belknap, David Holland, Pei-Jean Feng, Joan-Pau Millet, Joan A Caylà, Neil A Martinson, Alicia Wright, Michael P Chen, Ruth N Moro, Nigel A Scott, Bert Arevalo, José M Miró, Margarita E Villarino, Marc Weiner, Andrey S Borisov
Background: Expanding latent tuberculosis treatment is important to decrease active disease globally. Once-weekly isoniazid and rifapentine for 12 doses is effective but limited by requiring direct observation. Objective: To compare treatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observation. Design: An open-label, phase 4 randomized clinical trial designed as a noninferiority study with a 15% margin...
November 21, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29084120/tuberculosis-prevention-in-the-private-sector-using-claims-based-methods-to-identify-and-evaluate-latent-tuberculosis-infection-treatment-with-isoniazid-among-the-commercially-insured
#8
Erica L Stockbridge, Thaddeus L Miller, Erin K Carlson, Christine Ho
CONTEXT: Targeted identification and treatment of people with latent tuberculosis infection (LTBI) are key components of the US tuberculosis elimination strategy. Because of recent policy changes, some LTBI treatment may shift from public health departments to the private sector. OBJECTIVES: To (1) develop methodology to estimate initiation and completion of treatment with isoniazid for LTBI using claims data, and (2) estimate treatment completion rates for isoniazid regimens from commercial insurance claims...
October 27, 2017: Journal of Public Health Management and Practice: JPHMP
https://www.readbyqxmd.com/read/29025631/effect-of-isoniazid-preventive-therapy-on-risk-of-death-in-west-african-hiv-infected-adults-with-high-cd4-cell-counts-long-term-follow-up-of-the-temprano-anrs-12136-trial
#9
Anani Badje, Raoul Moh, Delphine Gabillard, Calixte Guéhi, Mathieu Kabran, Jean-Baptiste Ntakpé, Jérôme Le Carrou, Gérard M Kouame, Eric Ouattara, Eugène Messou, Amani Anzian, Albert Minga, Joachim Gnokoro, Patrice Gouesse, Arlette Emieme, Thomas-d'Aquin Toni, Cyprien Rabe, Baba Sidibé, Gustave Nzunetu, Lambert Dohoun, Abo Yao, Synali Kamagate, Solange Amon, Amadou-Barenson Kouame, Aboli Koua, Emmanuel Kouamé, Marcelle Daligou, Denise Hawerlander, Simplice Ackoundzé, Serge Koule, Jonas Séri, Alex Ani, Fassery Dembélé, Fatoumata Koné, Mykayila Oyebi, Nathalie Mbakop, Oyewole Makaila, Carolle Babatunde, Nathaniel Babatunde, Gisèle Bleoué, Mireille Tchoutedjem, Alain-Claude Kouadio, Ghislaine Sena, Sahinou-Yediga Yededji, Sophie Karcher, Christine Rouzioux, Abo Kouame, Rodrigue Assi, Alima Bakayoko, Serge K Domoua, Nina Deschamps, Kakou Aka, Thérèse N'Dri-Yoman, Roger Salamon, Valérie Journot, Hughes Ahibo, Timothée Ouassa, Hervé Menan, André Inwoley, Christine Danel, Serge P Eholié, Xavier Anglaret
BACKGROUND: Temprano ANRS 12136 was a factorial 2 × 2 trial that assessed the benefits of early antiretroviral therapy (ART; ie, in patients who had not reached the CD4 cell count threshold used to recommend starting ART, as per the WHO guidelines that were the standard during the study period) and 6-month isoniazid preventive therapy (IPT) in HIV-infected adults in Côte d'Ivoire. Early ART and IPT were shown to independently reduce the risk of severe morbidity at 30 months. Here, we present the efficacy of IPT in reducing mortality from the long-term follow-up of Temprano...
November 2017: Lancet Global Health
https://www.readbyqxmd.com/read/29025488/stigma-as-a-barrier-to-the-use-of-occupational-health-units-for-tuberculosis-services-in-south-africa
#10
N Sommerland, E Wouters, C Masquillier, M Engelbrecht, G Kigozi, K Uebel, A Janse van Rensburg, A Rau
SETTING: Tuberculosis (TB) is the leading cause of death in South Africa, and health care workers (HCWs) are disproportionally affected. The resulting absenteeism strains the already overburdened health system. Although hospital occupational health care units (OHUs) are cost-effective and of crucial importance in tackling the TB epidemic, the fear of being stigmatised by other colleagues might lead HCWs to avoid using OHUs. OBJECTIVE: To investigate whether the perception of TB stigma among colleagues has a negative effect on the willingness to use OHUs for TB services...
November 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/29025111/protective-effects-of-household-based-tb-interventions-are-robust-to-neighbourhood-level-variation-in-exposure-risk-in-lima-peru-a-model-based-analysis
#11
Jon Zelner, Megan Murray, Mercedes Becerra, Jerome Galea, Leonid Lecca, Roger Calderon, Rosa Yataco, Zibiao Zhang, Ted Cohen
Background: Untargeted active screening and treatment programmes for tuberculosis (TB) have not been shown to be more effective than passive screening and isoniazid preventive therapy (IPT) for reducing TB incidence. In this manuscript, we compare the efficacy of targeting screening and IPT on high-risk household contacts of diagnosed TB cases, with less-targeted active screening approaches in Lima, Peru. Methods: We conducted a population-based prospective cohort study within households of TB cases in Lima...
September 13, 2017: International Journal of Epidemiology
https://www.readbyqxmd.com/read/29023251/programmatic-evaluation-of-an-algorithm-for-intensified-tuberculosis-case-finding-and-isoniazid-preventive-therapy-for-people-living-with-hiv-in-thailand-and-vietnam
#12
Tori L Cowger, Le Hung Thai, Bui Duc Duong, Junya Danyuttapolchai, Somyot Kittimunkong, Nguyen Viet Nhung, Do Thi Nhan, Patama Monkongdee, Cao Kim Thoa, Vu Thi Khanh, Sriprapa Nateniyom, Nguyen Thi Bich Yen, Dong Van Ngoc, Tran Thinh, Sara Whitehead, Eric S Pevzner
BACKGROUND: Tuberculosis (TB) screening affords clinicians the opportunity to diagnose or exclude TB disease and initiate isoniazid preventive therapy (IPT) for people living with HIV (PLHIV). METHODS: We implemented an algorithm to diagnose or rule out TB among PLHIV in 11 HIV clinics in Thailand and Vietnam. We assessed algorithm yield and uptake of IPT and factors associated with TB disease among PLHIV. RESULTS: A total of 1448 PLHIV not yet on antiretroviral therapy (ART) were enrolled and screened for TB...
December 15, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28965312/a-comparison-of-adverse-drug-reaction-profiles-in-patients-on-antiretroviral-and-antitubercular-treatment-in-zimbabwe
#13
Josiah T Masuka, Precious Chipangura, Priscilla P Nyambayo, Andy Stergachis, Star Khoza
INTRODUCTION: Few studies describe the adverse drug event profiles in patients simultaneously receiving antiretroviral and anti-tubercular medicines in resource-limited countries. OBJECTIVES: To describe and compare the adverse drug reaction profiles in patients on highly active antiretroviral therapy only (HAART), HAART and isoniazid preventive therapy (HHART), and HAART and antitubercular treatment (ATTHAART). METHODS: We analysed individual case safety reports (ICSRs) for patients on antiretroviral therapy and antitubercular treatment submitted to the national pharmacovigilance centre during the targeted spontaneous reporting (TSR) programme from 1 September 2012 through 31 August 2016...
September 30, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28959695/fatal-pulmonary-embolism-in-the-setting-of-immune-reconstitution-inflammatory-syndrome-attributed-to-ovarian-tuberculosis
#14
Israel Ugalde, Daniela Pirela, Saberio Lo Presti, Molly Bilderback, Andrés Pirela, Joseph Chan
In developed countries, tuberculosis remains a health care challenge due to human immunodeficiency virus (HIV) and immigration from endemic regions. The Centers for Disease Control and Prevention reported 9557 new cases in 2015, with extrapulmonary involvement in 20.2% of the cases. We present a 33-year-old woman from Cape Town, South Africa, who developed abdominal pain and fever while working on a cruise ship. She sought medical where she underwent computed tomography of her chest, abdomen, and pelvis with findings suggestive of pulmonary tuberculosis and an 8...
July 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28949995/implementing-an-isoniazid-preventive-therapy-program-for-people-living-with-hiv-in-thailand
#15
Junya Danyuttapolchai, Somyot Kittimunkong, Sriprapa Nateniyom, Sutthapa Painujit, Virat Klinbuayaem, Nuanpun Maipanich, Yongyut Maokamnerd, Eric Pevzner, Sara Whitehead, Apiratee Kanphukiew, Patama Monkongdee, Michael Martin
Treatment of people living with HIV (PLHIV) with latent tuberculosis (TB) infection using isoniazid preventive therapy (IPT) can reduce the risk of TB disease, however, the scale-up of IPT among PLHIV in Thailand and worldwide has been slow. To hasten the implementation of IPT in Thailand, we developed IPT implementation training curricula and tools for health care providers and implemented IPT services in seven large government hospitals. Of the 659 PLHIV enrolled, 272 (41.3%) reported symptoms of TB and 39 (14...
2017: PloS One
https://www.readbyqxmd.com/read/28915796/correlates-of-isoniazid-preventive-therapy-failure-in-child-household-contacts-with-infectious-tuberculosis-in-high-burden-settings-in-nairobi-kenya-a-cohort-study
#16
Florence Nafula Okwara, John Paul Oyore, Fred Nabwire Were, Samson Gwer
BACKGROUND: Sub-Saharan Africa continues to document high pediatric tuberculosis (TB) burden, especially among the urban poor. One recommended preventive strategy involves tracking and isoniazid preventive therapy (IPT) for children under 5 years in close contact with infectious TB. However, sub-optimal effectiveness has been documented in diverse settings. We conducted a study to elucidate correlates to IPT strategy failure in children below 5 years in high burden settings. METHODS: A prospective longitudinal cohort study was done in informal settlings in Nairobi, where children under 5 years in household contact with recently diagnosed smear positive TB adults were enrolled...
September 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28911356/high-completion-rates-of-isoniazid-preventive-therapy-among-persons-living-with-hiv-in-swaziland
#17
L V Adams, N Mahlalela, E A Talbot, M Pasipamire, S Ginindza, M Calnan, S Haumba
SETTING: Five human immunodeficiency virus (HIV) care facilities in Swaziland. OBJECTIVE: To assess adherence and treatment completion of a 6-month course of isoniazid preventive therapy (IPT) provided to HIV-infected patients through a self-selected model of facility-based, community-based or peer-supported IPT delivery coordinated with antiretroviral refills. DESIGN: Prospective cohort study. RESULTS: Between February and August 2015, we enrolled 908 patients, with follow-up until February 2016...
October 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28885972/use-of-rifapentine-and-isoniazid-directly-observed-therapy-for-the-treatment-of-latent-tuberculosis-infection-in-a-military-clinic
#18
Janelle Jinbo, Michael Lustik, Gordon F West, Megan Kloetzel
BACKGROUND: There are 8.6 million cases of active tuberculosis (TB) worldwide, and an estimated one-third of the world population has latent tuberculosis infection (LTBI). In the United States, up to 80% of active cases may be caused by untreated reactivated latent infection. A case of TB can spread rapidly impacting the readiness of a unit. To prevent the development of TB, it is critical that active duty service members with LTBI complete treatment. The use of isoniazid (INH) and rifapentine (RPT) as a directly observed therapy (DOT) treatment option was recommended by the Centers for Disease Control and Prevention in late 2011...
September 2017: Military Medicine
https://www.readbyqxmd.com/read/28885271/isoniazid-preventive-therapy-completion-in-the-era-of-differentiated-hiv-care
#19
Khai Hoan Tram, Florence Mwangwa, Mucunguzi Atukunda, Asiphas Owaraganise, James Ayieko, Albert Plenty, Dalsone Kwariisima, Tamara D Clark, Maya L Petersen, Edwin D Charlebois, Moses R Kamya, Gabriel Chamie, Diane V Havlir, Carina Marquez
No abstract text is available yet for this article.
December 15, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28874368/immunodeficiency-and-intermittent-dosing-promote-acquired-rifamycin-monoresistance-in-murine-tuberculosis
#20
Sang-Won Park, Rokeya Tasneen, Paul J Converse, Eric L Nuermberger
More-permissive preclinical models may be useful in evaluating antituberculosis regimens for their propensity to select drug-resistant mutants. To evaluate whether acquired rifamycin monoresistance could be recapitulated in mice and, if so, to evaluate the effects of immunodeficiency, intermittent dosing, and drug exposures, athymic nude and BALB/c mice were infected. Controls received daily rifapentine alone or 2 months of rifampin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampin/isoniazid, either daily or twice weekly with one of two isoniazid doses...
November 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
30358
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"